U.S., April 9 -- ClinicalTrials.gov registry received information related to the study (NCT06916403) titled 'Safety and Efficacy of Ketamine Intravenous Infusions in the Treatment of Fibromyalgia' on March 24.
Brief Summary: Previous studies of intravenous ketamine, which is a non-competitive N-methyl-D aspartate receptor antagonist, for fibromyalgia pain relief are limited to three studies. Two studies have focused on short-term pain relief of intravenous ketamine by measuring the patients' pain levels immediately before and after the infusion. Currently, existing studies used short-term infusions (30-40 minutes) of sub-anesthetic doses of ketamine for pain relief in fibromyalgia patients, whereas the Consensus Guidelines on the Use of In...